# Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential

## TL;DR

This paper reviews how natural plant compounds can target cancer stem cells, which are tough to treat, and discusses how new delivery methods might improve their effectiveness.

## Contribution

The paper provides a comprehensive review of phytochemicals' mechanisms against cancer stem cells and evaluates nanotechnology-based delivery systems for improved therapeutic outcomes.

## Key findings

- Phytochemicals like curcumin and resveratrol disrupt cancer stem cell pathways and reduce their self-renewal and tumor-initiating potential.
- Nanotechnology-based delivery systems enhance the stability and targeting of phytochemicals in preclinical models.
- Phytochemicals sensitize cancer stem cells to chemotherapy by inhibiting drug-efflux transporters and promoting apoptosis.

## Abstract

Cancer stem cells (CSCs) represent a small but highly resilient tumor subpopulation responsible for sustained growth, metastasis, therapeutic resistance, and recurrence. Their survival is supported by aberrant activation of developmental and inflammatory pathways, including Wnt/β-catenin, Notch, Hedgehog, PI3K/Akt/mTOR, STAT3, and NF-κB, as well as epithelial–mesenchymal transition (EMT) programs and niche-driven cues. Increasing evidence shows that phytochemicals, naturally occurring bioactive compounds from medicinal plants, can disrupt these networks through multi-targeted mechanisms. This review synthesizes current findings on prominent phytochemicals such as curcumin, sulforaphane, resveratrol, EGCG, genistein, quercetin, parthenolide, berberine, and withaferin A. Collectively, these compounds suppress CSC self-renewal, reduce sphere-forming capacity, diminish ALDH+ and CD44+/CD24− fractions, reverse EMT features, and interfere with key transcriptional regulators that maintain stemness. Many phytochemicals also sensitize CSCs to chemotherapeutic agents by downregulating drug-efflux transporters (e.g., ABCB1, ABCG2) and lowering survival thresholds, resulting in enhanced apoptosis and reduced tumor-initiating potential. This review further highlights the translational challenges associated with poor solubility, rapid metabolism, and limited bioavailability of free phytochemicals. Emerging nanotechnology-based delivery systems, including polymeric nanoparticles, lipid carriers, hybrid nanocapsules, and ligand-targeted formulations, show promise in improving stability, tumor accumulation, and CSC-specific targeting. These nanoformulations consistently enhance intracellular uptake and amplify anti-CSC effects in preclinical models. Overall, the consolidated evidence supports phytochemicals as potent modulators of CSC biology and underscores the need for optimized delivery strategies and evidence-based combination regimens to achieve meaningful clinical benefit.